Cytheris Announces Publication of Clinical Case Study Combining Recombinant Human Interleukin-7 (CYT107) with Antiviral Agent CMX001 as Potential Treatment for Progressive Multifocal Leukoencephalopathy (PML)
Combination Therapy with Two Investigational Agents, Cytheris’ CYT107 and Chimerix’s CMX001, Indicates Potential for Clearing the JC Virus that Causes PML, a Rare and Usually Fatal Neurological Disease ...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768